18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Aug. 13 with a $31 million series A round. Eli Lilly...
10:03 , Aug 13, 2018 |  BC Extra  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Monday with a $31 million series A round. Participating in the...
01:12 , Jun 16, 2018 |  BioCentury  |  Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and a...
15:22 , May 4, 2018 |  BC Week In Review  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development Authority...
20:40 , Apr 27, 2018 |  BC Extra  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development Authority...
17:01 , Mar 16, 2018 |  BC Week In Review  |  Company News

IBM cognitive computing speeds Mayo trial enrollment

Mayo Clinic (Rochester, Minn.) and IBM Corp. (NYSE:IBM) said IBM’s Watson for Clinical Trials Matching cognitive computing system increased mean enrollment in Mayo’s systemic therapy clinical trials for breast cancer by 80% in its first...
20:49 , Feb 16, 2018 |  BC Week In Review  |  Company News

Teva, Allergan settle working capital dispute

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said Allergan plc (NYSE:AGN) agreed to pay Teva $700 million to settle a dispute that arose after Teva purchased Allergan's global generic pharmaceuticals business. In November 2017, Teva said...
21:02 , Jan 26, 2018 |  BC Week In Review  |  Company News

BIA intervenes on plausibility in patent law in Supreme Court case

The U.K. Bioindustry Association said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert Company LLC v. Generics UK Ltd and Actavis to examine the issue of plausibility in...